|
|
Biomarkers
|
|
Biomarkers
The discovery of protein biomarkers that cause disease or correlate with progression of disease will enable the development of new treatments and therapeutics to improve health outcomes.
The utility of the biomarker is not confined to the biomedical arena but can be applied to a wide range of sectors with agricultural and nutraceutical application.
Diabesity
Plasma biomarkers are proteins that exist in the blood which can be measured and used as a diagnostic tool as a predictor of disease. Diabesity is the term covering the two emerging diseases of modern society, diabetes and obesity.
BREAKING NEWS
January 2012 - Merck Millipore and Proteomics International announce collaboration for validation of biomarkers of diabetic nephropathy... media release
December 2011 - The world's leading mass spectrometer manufacturer, AB Sciex has released a Technote to illustrate Biomarker Discovery using Proteomics International's research pipeline for Diabetic Kidney Disease - AB Sciex link After three years of collaborative research involving patients from The Busselton Health Study, Proteomics International announced the discovery and analytical validation of 13 protein biomarkers for a significant complication of diabetes - diabetic nephropathy. Proteomics International is actively seeking partners to further qualify and commercialize its patented diabetes biomarker portfolio.
Historical news: Proteomics International has partnered with the world renowned Busselton Health Study and the University of Western Australia to find biomarkers for diabesity - Media Release - more
Proteomics International leads a collaborative study to identify protein biomarkers for diabesity. In partnership with the Centre for Food and Genomic Medicine, a Western Australian Centre of Excellence, the company uses a modified version of its Bioven process for discovery of causative biomarkers for diabetes and obesity. A biomarker can then be applied in the development of diagnostic and predictive tools to assess an individuals risk of developing the condition.
|
 |
|
 |